Find Funding Opportunities

Returning 144 results

NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32)

PAR
Monday, October 3, 2016
Sunday, September 8, 2019
F32
PAR-16-458

Funding Opportunity Purpose

The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in postdoctoral position. Based on the early timeframe of eligibility, and the discouragement of inclusion of preliminary data, this NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 3 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early fellowship application and timely completion of mentored training of the postdoctoral candidate in a single environment.

Support of Competitive Research (SCORE) Pilot Project Award (SC2)

PAR
Wednesday, September 21, 2016
Workforce Diversity
Sunday, September 8, 2019
PAR-16-438

Funding Opportunity Purpose

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and research capacity of institutions with an explicitly stated historical mission and/or a demonstrated historical track record of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

Support of Competitive Research (SCORE) Research Advancement Award (SC1)

PAR
Wednesday, September 21, 2016
Workforce Diversity
Sunday, September 8, 2019
PAR-16-439

Funding Opportunity Purpose

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated historical track record of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

Engineering Next-Generation Human Nervous System Microphysiological Systems (R01)

PAR
Thursday, August 11, 2016
Wednesday, January 8, 2020
R01
PAR-16-398

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) with improved fidelity to complex human brain, spinal, peripheral nervous system and/or sensory end organ circuit physiology in vivo, which will ultimately facilitate analysis of higher order functional deficits relevant to complex nervous system disorders.

Engineering Next-Generation Human Nervous System Microphysiological Systems (R21)

PAR
Thursday, August 11, 2016
Wednesday, January 8, 2020
R21
PAR-16-397

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) with improved fidelity to complex human brain, spinal, peripheral nervous system and/or sensory end organ circuit physiology in vivo, which will ultimately facilitate analysis of higher order functional deficits relevant to complex nervous system disorders.

Research on Autism Spectrum Disorders (R21)

PA
Friday, August 5, 2016
Sunday, September 8, 2019
R21
PA-16-386

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD).

Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03)

PAR
Wednesday, June 29, 2016
Sunday, September 8, 2019
R03
PAR-16-348

Funding Opportunity Purpose

The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and ultimately more targeted therapies, as well as to develop an integrated pediatric research data resource by obtaining and aggregating genome sequence and phenotype data for as many relevant structural birth defects and pediatric cancer cohorts as possible and to advance research in this area through the broad sharing of these data with the research community. This FOA is intended to promote meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.

Career Transition Award for NINDS Intramural Clinician-Scientists (K22)

PAR
Thursday, June 23, 2016
Training, Career Development
Wednesday, May 8, 2019
K22
PAR-16-340
Stephen Korn

Funding Opportunity Purpose

The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.

Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01)

PAR
Wednesday, June 15, 2016
Translational Research
Wednesday, September 12, 2018
U01
PAR-16-330
David Yeung

Funding Opportunity Purpose

The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests new research applications for Cooperative Agreement Research Projects (U01s) seeking support for research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. The scope of research supported by this FOA includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data. These studies should result in the identification of at least one lead compound ready for optimization. Lead compounds are biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. Lead compounds should be ready for more advanced development under possible support from other programs such as the one described in the companion FOA "CounterACT Optimization of Therapeutic Lead Compound (U01)" (PAR-16-331). The scope of this FOA encompasses Technical Readiness Level (TRL) 3 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)

PAR
Wednesday, June 15, 2016
Translational Research
Wednesday, September 12, 2018
U01
PAR-16-331
David Yeung

Funding Opportunity Purpose

The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests research applications seeking support for research on the optimization of small molecule or biologic compounds that are excellent candidates for therapeutic development. A previously identified lead compound is required to be eligible for this funding opportunity. In this regard, lead compounds are defined as biologically active compounds or hits where affinity, potency, target selectivity, and preliminary safety have been established. The scope of research supported by this FOA includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans. It also includes bioanalytical assay development and validation, laboratory-scale and scale-up manufacturing of the product, and non-GLP toxicity and pharmacology studies. The scope of this FOA encompasses Technical Readiness Levels (TRLs) 4-5 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

Pages